louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02430636: Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms
Official title: Irreversible Electroporation(IRE) For Unresectable Stmoach Neoplasms: Phase I and Phase II Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stomach Neoplasms
Keywords: irreversible electroporation
Unresectable Stomach Neoplasms
Lead sponsor: Fuda Cancer Hospital, Guangzhou
Sponsor class: OTHER
First posted: 2015-04-30
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Stomach Neoplasms.

Detailed description: By enrolling patients with unresectable Head and Stomach adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Stomach Neoplasms.

Eligibility criteria: Inclusion Criteria:

* Stomach Neoplasms diagnosed by positive biopsy or non-invasive criteria,
* Not suitable for surgical resection,
* Eastern Cooperative Oncology Group (ECOG) score of 0-1,
* A prothrombin time ratio \> 50%,
* Platelet count \> 80x10\^9/L,
* Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
* Able to comprehend and willing to sign the written informed consent form (ICF),
* Have a life expectancy of at least 3 months.

Exclusion Criteria:

* Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
* Any active implanted device (eg Pacemaker),
* Women who are pregnant or women of child-bearing potential who are not using an acceptable method of contraception,
* Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
* Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.

Primary outcomes:
measure: Number of participants with Adverse events
timeFrame: 6 month
Secondary outcomes:
measure: Percentage of lesions that show no sign of recurrence 12 months after IRE
timeFrame: 12 months
measure: A minimum and maximum range of voltage for safe and effective IRE
timeFrame: 3 months
measure: Progress free disease (PFS)
timeFrame: 12 months
measure: Overall survival (OS)
timeFrame: 36 months
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Biological treatment center in Fuda cancer hospital
state: Guangdong
Study officials:
affiliation: Fuda Cancer Hospital
name: Lizhi Niu, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT07011836: Video-Based Patient Navigation to Support Cervical Cancer Screening Among Black Women
Official title: Enhancing the Effectiveness of Community Health Workers to Reduce Cervical Cancer Disparities in African American Women
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Uterine Cervical Neoplasms
Keywords: Early Detection of Cancer
Health Behavior
Patient Navigation
African Americans
Lead sponsor: ISA Associates, Inc.
Sponsor class: OTHER
Collaborators: name: National Institute on Minority Health and Health Disparities (NIMHD)
First posted: 2025-06-10
Enrollment: 288
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The goal of this clinical trial is to test whether an interactive, video-based patient navigation program can improve cervical cancer screening among African American women who are currently overdue for screening.

The main questions it aims to answer are:

Can an interactive video navigation tool (mNav), when paired with in-person navigation, improve screening adherence compared to a standard educational video alone?

Does the intervention improve knowledge, reduce barriers, and increase intentions to get screened?

Researchers will compare participants who receive both the interactive video (guided by an on-screen navigator) and in-person navigation to those who receive only a standard educational video to see if the tailored support increases screening rates.

Participants will:

Complete two phone surveys (one at the beginning and one six months later)

Be randomly assigned to one of two groups:

One group will receive an interactive video experience tailored to their concerns plus support from an in-person navigator

The other group will receive a standard educational video designed for African American women

Have their clinic records reviewed six months later to check for cervical cancer screening completion


Eligibility criteria: Inclusion Criteria:

* Black or African American woman
* Nonadherent to USPSTF cervical cancer screening guidelines (no Pap test in the past 3 years or no HPV test in the past 5 years)
* Age 21 to 65 years old
* Not currently pregnant
* No history of hysterectomy
* Access to a mobile phone capable of receiving text messages and watching video content

Exclusion Criteria:

\*None

Primary outcomes:
measure: Completion of Cervical Cancer Screening
timeFrame: Within 6 months of enrollment
Secondary outcomes:
measure: Cervical Cancer Screening Intention
timeFrame: Baseline and 6-month follow-up
measure: Cervical Cancer Knowledge Scale
timeFrame: Baseline and 6-month follow-up
Other outcomes:
Locations:
city: Arlington
country: United States
facility: ISA Associates
state: Virginia
Study officials:
References:
Clinical trial NCT04586036: The Evaluation of Ankle Joint Braces Efficiency
Official title: The Evaluation of Ankle Joint Braces Efficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ankle Injuries
Ankle Sprains
Keywords: ankle joint brace
atfl
oxford foot model
Lead sponsor: Józef Piłsudski University of Physical Education
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The project concerns the evaluation of commercially available ankle joint braces effectiveness used as orthopedic supply after ankle joint ligaments tear injury. Authors hypothesize that the restriction of range of motion may be not sufficient in the early healing process.


Eligibility criteria: Inclusion Criteria:

* age 18-35
* female or male
* good health condition
* chronic ankle joint instability (for chronic ankle instability group)

Exclusion Criteria:

* lower limb injuries (last 6 months)
* extreme sports athletes
* no chronic ankle joint instability (for chronic ankle instability group)

Primary outcomes:
measure: Oxford Foot Model Angles
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Józef Piłsudski University of Physical Education in Warsaw
state: Mazowsze
Study officials:
References:
Clinical trial NCT00929136: Peripheral Effects of Endotoxin on Insulin Resistance
Official title: The Effect of Regional Inflammation on Metabolism and Insulin Sensitivity in the Lower Extremity.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Endotoxin
Insulin resistance
Lipolysis
Proteolysis
Intracellular Insulin Signaling
Regional effects of inflammation/endotoxin
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
First posted: 2009-06-26
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to isolate the direct effects of endotoxin on glucose, lipid and protein metabolism. Eight healthy volunteers are enrolled. The hypothesis is that endotoxin will induce insulin resistance, lypolysis and proteolysis acutely.


Eligibility criteria: Inclusion Criteria:

1. Normal health
2. 22 \< BMI \< 28
3. Written Informed Concent

Exclusion Criteria:

1. Any disease
2. Any use of medication
3. Recent immobilization of a lower extremity

Primary outcomes:
measure: glucose concentration
timeFrame: 360 minutes observation
Secondary outcomes:
measure: Regional arteriovenous amino-acid balance
timeFrame: measured at t=180 and 360 minutes
measure: Intra-cellular insulin signaling
timeFrame: measured at t=0, 120, and, 210 minutes
measure: Regional arteriovenous lipid balance
timeFrame: measured at t=180 and 360 minutes
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: The Medical Research Laboratories, Dept. M, Aarhus University Hospital
Study officials:
affiliation: Medical Department M (Endocrinology and Diabetes), Århus University Hospital, Denmark
name: Mads Buhl, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, Denmark
name: Niels Moller, M.D., professor, Dmsc
role: STUDY_DIRECTOR
References:
citation: Buhl M, Bosnjak E, Vendelbo MH, Gjedsted J, Nielsen RR, K-Hafstrom T, Vestergaard ET, Jessen N, Tonnesen E, Moller AB, Pedersen SB, Pilegaard H, Bienso RS, Jorgensen JO, Moller N. Direct effects of locally administered lipopolysaccharide on glucose, lipid, and protein metabolism in the placebo-controlled, bilaterally infused human leg. J Clin Endocrinol Metab. 2013 May;98(5):2090-9. doi: 10.1210/jc.2012-3836. Epub 2013 Mar 29.
Clinical trial NCT00002349: A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.
Official title: A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: AIDS-Related Complex
Stavudine
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To compare the antiviral effect of stavudine ( d4T ) versus placebo in patients with evidence of recent HIV infection.

Also, to compare the immunologic effects and effects on quality of life of d4T in these patients.

Detailed description: Patients receive d4T or placebo every 12 hours for 4 weeks, after which dose decreases (or placebo) every 12 hours. Treatment continues for at least 48 weeks.

Eligibility criteria: Inclusion Criteria

Patients must have:

* Recent HIV infection.
* No prior antiretroviral therapy.
* No acute opportunistic infection at study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Intractable diarrhea.
* Bilateral peripheral neuropathy.
* Any other condition that would preclude study therapy.

Concurrent Medication:

Excluded:

* Myelosuppressive, neurotoxic, or hepatotoxic drugs.

Patients with the following prior condition are excluded:

History of bilateral peripheral neuropathy.

Prior Medication:

Excluded:

* Prior antiretroviral therapy.
* Myelosuppressive, neurotoxic, or cytotoxic agents within 3 months prior to study entry.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: San Diego Naval Hosp
state: California
city: Portsmouth
country: United States
facility: Naval Med Ctr
state: Virginia
city: Seattle
country: United States
facility: Northwest Med Ctr
state: Washington
Study officials:
name: . ., .
role: PRINCIPAL_INVESTIGATOR
References:
citation: Katlama C, Molina JM, Rozenbaum W, Valantin MA, Modai J, Chauveau E, Ngo Van P, Gres JJ. Stavudine ( D4T ) in HIV infected patients with CD4 less than 350/mm3: results of a double-blind randomized placebo controlled study. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:89
Clinical trial NCT05203536: Respiratory Mechanics Assessment During Assisted Mechanical Ventilation
Official title: ICEBERG STUDY. Respiratory Mechanics Assessment During Assisted Mechanical Ventilation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Hypoxemic Respiratory Failure
Lead sponsor: University of Milano Bicocca
Sponsor class: OTHER
First posted: 2022-01-24
Enrollment: 298
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: AHRF/ARDS patients on Assisted Mechanical Ventilation modes from international centers will be enrolled. All the pressure-targeted modes of assisted ventilation will be acceptable for the study inclusion.

Brief summary: To verify the association between respiratory system mechanical properties (ΔP, ΔPL,dyn, Pmus, Pplat and CRS and CL,dyn) assessed during assisted modes of ventilation (as average over the first three days since enrollment) and ICU mortality.


Eligibility criteria: Inclusion Criteria:

* Acute Hypoxaemic Respiratory Failure (defined as respiratory failure requiring invasive mechanical ventilation with a PaO2/FiO2\< 300 mmHg) during the course of ICU stay (including ARDS).
* Invasive mechanical ventilation in one of these modes: Pressure A/C, PRVC, SIMV PC, PSV, NAVA, PAV+, BiPAP
* Presence of spontaneous breathing activity (ventilator triggering), since 6 hours and no longer than 48 hours
* Patient for full active management at this point.

Exclusion Criteria:

* Age \<18 years old
* Pregnancy
* Active air leaks
* Moribund state
* High ICP
* Patient has passed a spontaneous breathing trial (if performed for clinical indication)
* Known COPD with history of home oxygen therapy and/or non invasive ventilation and/or GOLD III-IV. Non invasive ventilation for sleep apnea is NOT an exclusion criteria.

Primary outcomes:
measure: Correlation between respiratory system mechanical properties and ICU mortality
timeFrame: 90 days
Secondary outcomes:
measure: Correlation between respiratory system compliance and ICU mortality
timeFrame: 90 days
measure: Correlation between plateau pressure and ICU mortality
timeFrame: 90 days
measure: Correlation between pressure muscle index and ICU mortality
timeFrame: 90 days
measure: Correlation between muscle pressure and ICU mortality
timeFrame: 90 days
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto General Hospital
city: Kiel
country: Germany
facility: University Medical Centre Schleswig-Holstein
city: Galway
country: Ireland
facility: University Hospital Galway
city: Ferrara
country: Italy
facility: Ospedale Sant'Anna
city: Milano
country: Italy
facility: Policlinico di Milano Ospedale Maggiore
city: Monza
country: Italy
facility: ASST-Monza, Ospedale San Gerardo
city: Barcelona
country: Spain
facility: Vall d'Hebron University Hospital
city: Barcelona
country: Spain
facility: Hospital Clinic de Barcelona
Study officials:
References:
Clinical trial NCT03873636: Altering Multitasking Behavior Using Low Current Brain Stimulation
Official title: Altering Multitasking Behavior Using Low Current Brain Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cognitive Change
Lead sponsor: Tufts University
Sponsor class: OTHER
First posted: 2019-03-13
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study is designed to investigate multitasking deficits, with a particular interest in reducing costs related to dual-tasking (dividing attention between tasks) and task-switching (switching between tasks) using noninvasive brain stimulation.


Eligibility criteria: Inclusion Criteria:

* Must be able to participate in non invasive brain stimulation research
* Must be a fluent English speaker
* Must be at least 18 years old
* Must be right-handed
* Must have normal or corrected-to-normal vision

Exclusion Criteria:

* Any history of complications with non invasive brain stimulation research
* Any metallic implants in head
* Any implanted internal or external electrical stimulation device
* Any adverse reaction to tDCS or other forms of low current brain stimulation
* Any history of seizure
* Any history of head injury
* Any illness that caused brain injury
* Any other brain-related condition
* Any diagnosis of neurological or psychiatric disorder
* A sensitive scalp

Primary outcomes:
measure: Response accuracy
timeFrame: 4 hours
measure: Response latency
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Medford
country: United States
facility: Tufts University
state: Massachusetts
Study officials:
affiliation: Tufts University
name: Nathan Ward, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05652049: Using New Ultrasound Techniques to Assess Peritoneal Fibrosis in Peritoneal Dialysis Patients
Official title: An Exploratory Study Using New Ultrasound Techniques to Assess Peritoneal Fibrosis and Encapsulating Peritoneal Sclerosis in Peritoneal Dialysis Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peritoneal Sclerosis
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2022-12-15
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: End-stage renal diseases（ESRD） patients on PD

Brief summary: Explore the role of new ultrasound techniques in the assessment of peritoneal fibrosis and encapsulating peritoneal sclerosis in peritoneal dialysis patients


Eligibility criteria: Inclusion Criteria:

* ESRD patients on PD
* PD duration ≤12 months or ≥10 years
* Age between 18-75years

Exclusion Criteria:

* Refusing to sign up informed consent

Primary outcomes:
measure: parietal peritoneal fibrosis
timeFrame: the 1 day when being recruited
Secondary outcomes:
measure: encapsulting peritoneal sclerosis
timeFrame: the 1 day when being recruited
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Renji Hospital, Shanghai Jiaotong University School of Medicine
state: Shanghai
Study officials:
References:
Clinical trial NCT05330949: Optical Coherence Tomography Angiography Compared to Maternal Doppler in Screening for Hypertension in Pregnancy
Official title: Retinal Microvascular Changes by Optical Coherence Tomography Angiography Compared to Maternal Uterine Artry Doppler in Screening for Hypertensive Disorders in High-risk Pregnancies
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pregnancy Induced Hypertension
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2022-04-15
Enrollment: 60
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 45
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: two groups according to the risk of developing hypertension during pregnancy

Brief summary: Pregnancy related hypertension is one of the most prevalent obstetric complications. The aim of the study is to evaluate the validity and sensitivity of OCT angiography in prediction of pregnancy induced hypertensive disorders in comparison to maternal doppler in the first and second trimesters of pregnancy


Eligibility criteria: Inclusion Criteria:

* Pregnant women in the first and second trimesters

Exclusion Criteria:

* pregnant females with associated systemic vascular disease as diabetes, SLE

Primary outcomes:
measure: validity and sensitivity of OCT angiography
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Minia University
state: Minia Governorate
Study officials:
References:
Clinical trial NCT01293149: Clonidine in Femoral Nerve Block Surgery in Children
Official title: The Effects of Clonidine on Postoperative Analgesia After Single Shot Femoral Nerve Block Following Arthroscopic Knee Surgery in Children
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Other Reconstructive Surgery
Keywords: knee, reconstructive surgery
femoral nerve block
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2011-02-10
Enrollment: 0
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Knee arthroscopy is a common surgical procedure in pediatrics in which the knee joint is visualized through a small camera to help diagnose and treat knee problems. This procedure is commonly accomplished with the use of general anesthesia. Regional anesthesia is commonly completed with a single injection of local anesthetic around the femoral nerve to provide pain relief for several hours following knee arthroscopy. The intent of this study is to examine the effects of clonidine in addition to local anesthetics for femoral nerve blockade in providing children and adolescents post-operative analgesia. The investigators hypothesize the addition of low dose clonidine (1 mcg/kg) provides an additional 4 hours of post operative analgesia following arthroscopic knee surgery and reduces post-operative opiate requirement.


Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiologist (ASA) functional status I or II
* Patients scheduled for arthroscopic knee surgery only

Exclusion Criteria:

* Patients with history of chronic opioid therapy, central or peripheral neuropathy, contraindications to regional anesthesia, history of allergy to clonidine or ropivicaine, or anterior cruciate ligament reconstructive surgery in addition to knee arthroscopy

Primary outcomes:
measure: Pain
timeFrame: 24 hours
Secondary outcomes:
measure: Heart rate
timeFrame: 15, 30 & 60 mins. post-op
measure: Blood pressure
timeFrame: 15, 30 & 60 mins. post-op
measure: Oxygen saturation
timeFrame: 15, 30 & 60 mins. post-op
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
affiliation: Nationwide Children's Hospital
name: Amod Sawardekar, MD
role: PRINCIPAL_INVESTIGATOR
References: